Condition: Relapsed/refractory High Grade B Cell Lymphoma · High Grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma Relapsed · Sponsor: Sung-Soo Park
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is: Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies? Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes. Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.
This description comes directly from the study's public registry record.
Sung-Soo Park, MD. PhD. · +82-02-2258-6754 · sspark@catholic.ac.kr
Young-Woo Jeon, MD. PhD. · +82-10-2691-4067 · native47@catholic.ac.kr
Always discuss trial participation with your own doctor first.
| Seoul St. Mary Hospital | Seoul, South Korea | Recruiting |
| Yeoido St. Mary Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06796517